Considered the father of Japanese medicine, Dr. Kitasato Shibasaburo was a renowned physician and bacteriologist whose face will appear on Japan’s ¥1,000 bank note in 2024. More than 100 years ago, he founded Terumo Corp. in Tokyo as a thermometer manufacturer.
Today, Terumo comprises three companies, generates more than $5.58 billion (about ¥820 billion) annually as of March, and employs more than 30,000 associates around the world, all dedicated to contributing to society through health care.
Shibasaburo’s legacy has continued to inspire Terumo Blood and Cell Technologies in Lakewood, Colorado, for the past 56 years. A hospitable location for business innovation, Colorado is the home of many international companies, including Japanese aerospace company ispace Inc. Globally, Terumo BCT has 7,900 associates, seven manufacturing facilities and 400 distributors in more than 150 countries.
Terumo BCT’s sales revenues grew 8% from fiscal 2021 to fiscal 2022, with forecasts for 2023 looking positive.
Driven by a legacy of excellence of more than half a century, Terumo BCT keeps patients at the heart of everything it does. It has four areas of focus: innovation, automation, access to care and collaboration.
From lifesaving blood transfusions to next-generation therapies, Terumo BCT capitalizes on its knowledge of blood and cells as essential components to develop an extensive range of treatments. Its purpose-driven employees and innovations play an important role in the collection, processing, development and delivery of those treatments.
Together with the global health care system, Terumo BCT is unlocking the potential of blood and cells to benefit patients even more.
